Treatment with HMG-CoA reductase inhibitors - More than lipid lowering?;Therapie mit CSE-Hemmern - Mehr als lipidsenkung?

Herz

Volumn 24, Issue 1, 1999, Pages 42-45

  Weizel, Achim ^a  

^a Medizinische Klinik   (Germany)

Author keywords

Angina pectoris; HMG CoA reductase inhibitors; Lipid lowering; Myocardial infarction

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; HEART TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERLIPIDEMIA; MORTALITY; REVIEW; RISK FACTOR; SECONDARY PREVENTION;

EID: 0033027504     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03043817     Document Type: Review

References (60)

1. Anderson TJ, Meredith IT, Yeung AC, et al. The effect of cholesterol lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995;332:488-93.
2. Andrade SE, Walker AM, Lawrence PH, et al. Discontinuation of antihyperlipidemic drugs - do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995;332:1125-31.
3. Andrews TC, Raby K, Berry J, et al. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation 1997;95:324-8.
4. Athyros VG, Papagcorgiou AA, Hatzikonstandinou HA, et al. Effect of atorvastatin versus simvastatin on lipid profile and plasma fibrinogen in patients with hypercholesterolemia. A pilot, randomized, double-blind, dose-titration study. Clin Drug Invest 1998;16:219-27.
5. AVERT-Studie (Atorvastatin versus Revascularisation Treatment). American Heart Association. 71st Scientific Session, Dallas, Texas, November 9.-11. 1998.
6. Bellosta S, Bernini F, Ferri N, et al. Direct vascular effects of HMG CoA reductase inhibitor. Atherosclerosis 1998;137:Suppl:101-9.
7. Bestehorn HP, Rensing FE, Roskamp H, et al. The effect of simvastatin on progression of coronary artery disease. The multicenter coronary intervention study (CIS). Eur Heart J 1997;18:226-34.
8. Blankenhorn DH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy. The monitored atherosclerosis regression study (MARS). The MARS research group. Ann Intern Med 1994;119:969-76.
9. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986;232:34-47.
10. Buchwald H, Varco RL, Matts JP. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. N Engl J Med 1990;323: 946-55.
11. Crouse JR III, Byington RP, Bond MG, et al. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC II). Am J Cardiol 1995;75:455-9.
12. Davidson M, McKenney J, Stein E, et al. for the atorvastatin study group I: Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Am J Cardiol 1997;79:1475-81.
13. Downs JR, Clearfiled M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. J Am Med Ass 1998;279:1615-22.
14. Drexler H, Zeiher HM, Meinzer K, et al. Correction of endothelial dysfunction in the coronary microcirculation of hypercholesterolemic patients by L-arginine. Lancet 1991;338:1546-50.
15. Egashira K, Horooka Y, Kai H, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994;89:2519-24.
16. Frick MH, Elo O, Haapa K, et al. Helsinki Heart study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987;317:1237-45.
17. Hansson GK, Holm J, Jonasson L. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol 1989;135:169-75.
18. Hebert PR, Gaziano JM, Chan KS, et al. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. J Am Med Ass 1997;278:313-21.
19. Herd JA, Ballantyne CM, Fermer JA. et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (lipoprotein and coronary atherosclerosis study [LCAS]). Am J Cardiol 1997;80:278-86.
20. Jones P, Kavonek S, Laurora I, et al. for the CURVES Investigators: Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES Study). Am J Cardiol 1998;81:582-7.
21. Jukema JW, Bruschke AVG, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The regression growth evaluation statin study (REGRESS). Circulation 1995;91:2528-40.
22. Kannel WB. Range of serum cholesterol values in the population developing coronary heart disease. Am J Cardiol 1995;76: 69C-77C.
23. Keech A. Does cholesterol lowering reduce total mortality? Postgrad Med J 1992;68:870-1.
24. Keys A. Seven countries. A multivariate analysis of death and coronary heart disease. Cambridge, Mass:Harvard University Press, 1980.
25. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995;333:621-7.
26. Libby P. Molecular basis of acute coronary syndromes. Circulation 1995;91:2844-50.
27. Libby P, Aiakawa M. New insights into plaque stabilisation by lipid lowering. Drugs 1989;56:Suppl 1:9-13.
28. Long Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
29. MAAS Investigators. Effect of simvastatin on coronary atheroma: the multicentrc anti-atheroma study (MAAS). Lancet 1994;344:633-8.
30. Marais AD, Firth JC, Bateman ME, et al. Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1997;17:1527-31.
31. Miettinen TA, Pyorälä K, Olsson AG, et al. Cholesterol lowering therapy in women and elderly patients with myocardial infarction or angina pectoris. Circulation 1997;96:4211-8.
32. Müller-Wieland D, Faust M, Krone W. Cholesterinsynthesehemmer. Internist 1998;39:934-42.
33. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenxyme A reductase inhibitor improves endothelial function within 1 month. Circulation 1997;95:1126-31.
34. Otto C, Sehwandt P. Gibt es Unterschiede zwischen verschiedenen Statinen? Internist 1998;39:987-93.
35. Pedersen TR, Olsson AG, Faergeman O, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study. Circulation 1998;97:1453-60.
36. Pitt B, Mancini GBJ, Ellis SG, et al. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol 1995;26:1133-9.
37. Pyörälä K, Pedersen T, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4 S). Diah Care 1997;20:614-20.
38. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998;97:2007-11.
39. Ridker PM, Nader R, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998;98:839-44.
40. Rosenson RS, Tagney CC. Antiatherothrombotic properties of statins. J Am Med Ass 1988;279:1643-50.
41. Sacks FM, Moye LA, Davis BD, et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the cholesterol and recurrent events trial. Circulation 1998;97:1446-52.
42. Sacks FM, Paternak RC, Gibson CM, et al. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolemic patients. Lancet 1994;344:1182-6.
43. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 1996;335:1001-9.
44. Salonen R, Nyysönen K, Porkkala E, et al. Kuopio atherosclerosis prevention study (KAPS). Circulation 1995;92:1758-64.
45. Scandinavian simvastatin survival study group. Randomized trial of cholesterol lowering in 4 444 patients with coronary heart disease. The Scandinavian simvastatin survival study (4S). Lancet 1994;344:1383-9.
46. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
47. Tamura A, Mikuriya A, Nasu M, Effect of pravastatin (10 mg/day) on progression of coronary atherosclerosis in patients with serum cholesterol levels from 160 bis 220 mg/dl and angiographically documented coronary artery disease. Am J Cardiol 1997;79:893-6.
48. The Lipid Research Clinics Program: The lipid research clinics coronary primary prevention trial results: I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64.
49. The MRFIT Research Group. Multiple risk factor intervention trial. Risk factor changes and mortality results. JAMA 1982;248:1465-77.
50. The post coronary artery bypass graft trial investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low dose anticoagulation on obstructive changes in saphenous vein coronary-artery bypass grafts. N Engl J Med 1997;336:153-62.
51. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332: 481-7.
52. Van Boven AJ, Jukema JW, Zwinderman AH, et al. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. Regress Group Study. Circulation 1996;94:1503-5.
53. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 1996;348:1079-82.
54. Violaris AG, Melker R, Serruys PW. Influence of serum cholesterol and cholesterol subfractions on restenosis after successful coronary angioplasty. A quantitative angiographic analysis of 3336 lesions. Circulation 1994;90:2267-79.
55. Vogel RA, Corretti MC, Plottnick GD. Changes in flow-mediated brachial artery vasoactivity with lowering desirable cholesterol levels in healthy middle-aged men. Am J Cardiol 1996;77: 37-40.
56. Waters D, Higginson L, Gladstone P, et al. Effect of monotherapy with a HMG CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriograpy: the Canadian coronary atherosclerosis intervention trial. Circulation 1994;89:559-68.
57. Watts GF, Burke V, Lewis B. Plasma low density lipoprotein cholesterol levels and progression/regression of coronary atherosclerosis: a meta-regression analysis of angiographic trials. Br J Cardiol 1997;4:64-70.
58. Weintraub WS, Boccuzzi SJ, Klein L, et al. Lack of effect of lovastatin on restenosis after coronary angioplasty. New Engl J Med 1994;331:1331-7.
59. West of Scotland Coronary Prevention Group. West of Scotland Coronary Prevention Study. Identification of high risk groups and comparison with other cardiovascular intervention trials. Lancet 1996;348:1339-42.
60. Wierzbicki AS, Lumb PJ, Semra YK, et al. Effect of atorvastatin on fibrinogen. Lancet 1998;351:569-70.